Description
ADCC-Enhanced anti-ACVRL1 (ActRIIa-mFc) is a non-fucosylated therapeutic biobetter antibody engineered by Creative Biolabs' Afuco™ technology platform.
Antibody Indication
Urothelial Cancer
Classification
Therapeutic antibody; biobetter
Cooperation Seeking
Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced ACVRL1 antibody. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
ACVRL1
Full Name
activin A receptor type II-like 1
Background
This gene encodes a type I cell-surface receptor for the TGF-beta superfamily of ligands. It shares with other type I receptors a high degree of similarity in serine-threonine kinase subdomains, a glycine- and serine-rich region (called the GS domain) preceding the kinase domain, and a short C-terminal tail. The encoded protein, sometimes termed ALK1, shares similar domain structures with other closely related ALK or activin receptor-like kinase proteins that form a subfamily of receptor serine/threonine kinases. Mutations in this gene are associated with hemorrhagic telangiectasia type 2, also known as Rendu-Osler-Weber syndrome 2.
Alternative Names
ACVRL1; activin A receptor type II-like 1; HHT; ALK1; HHT2; ORW2; SKR3; ALK-1; TSR-I; ACVRLK
Gene ID
94
UniProt ID
P37023
Cellular Localization
Plasma membrane
Involvement in Disease
Diseases associated with ACVRL1 include Telangiectasia, Hereditary Hemorrhagic, Type 2 and Pulmonary Hypertension, Primary, 1.
Related Pathways
Its related pathways are Akt Signaling and PEDF Induced Signaling.
Function
Type I receptors of TGF-β family ligands BMP9/GDF2 and BMP10 and important regulators of normal vascular development. After the ligand binds, a receptor complex composed of two type II and two type I transmembrane serine/threonine kinases is formed. Type II receptors phosphorylate and activate type I receptors, which automatically phosphorylate and then bind and activate SMAD transcriptional regulators. It can also be combined with activin.
Field of research
Cell Biology and Cellular Response antibody; Metabolism antibody; Signaling Transduction antibody
Post-translational modifications
1.Glycosylation at Asn98 2.Modification sites at PhosphoSitePlus
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Isotype
IgG
Antibody Clone
ActRIIa-mFc
Description
ADCC-Enhanced anti-ACVRL1 (ActRIIa-mFc) is a non-fucosylated therapeutic biobetter antibody engineered by Creative Biolabs' Afuco™ technology platform.
Antibody Indication
Urothelial Cancer
